Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Since the introduction of nab-paclitaxel plus gemcitabine (nab-P+GEM) as first-line (1L) treatment for metastatic pancreatic adenocarcinoma (mPDAC), optimal second-line (2L) chemotherapy after progression is unclear. We assessed clinical outcomes of 2L chemotherapy for disease that progressed on 1L nab-P+GEM. Materials and Methods Among the 203 patients previously treated with 1L nab-P+GEM for mPDAC at Asan Medical Center, between February and December 2016, records of 120 patients receiving 2L chemotherapy after progression on nab-P+GEM were retrospectively reviewed. The response rate and survival were evaluated along with analysis of prognostic factors. Results Fluoropyrimidine-oxaliplatin doublets (FOLFOX or XELOX) were used in 78 patients (65.0%), fluoropyrimidine monotherapy in 37 (30.8%), and liposomal irinotecan plus fluorouracil in two (1.7%). The median progression-free survival (PFS) and overall survival (OS) were 3.29 months and 7.33 months from the start of 2L therapy. Fluoropyrimidine-oxaliplatin regimens and fluoropyrimidine monotherapy did not yield significantly different median PFS (2.89 months vs. 3.81 months, p=0.40) or OS (7.04 months vs. 7.43 months, p=0.86). A high neutrophil-lymphocyte ratio (> 2.2) and a short time to progression with 1L nab-P+GEM (< 6.4 months) were independent prognostic factors of poor OS with 2L therapy. Conclusion 2L fluoropyrimidine-oxaliplatin doublets and fluoropyrimidine monotherapy after failure of 1L nab-P+GEM had modest efficacy, with no differences in treatment outcomes between them. Further investigation is warranted for the optimal 2L chemo-regimens and sequencing of systemic chemotherapy for patients with mPDAC.
Abstract
Purpose Since the introduction of nab-paclitaxel plus gemcitabine (nab-P+GEM) as first-line (1L) treatment for metastatic pancreatic adenocarcinoma (mPDAC), optimal second-line (2L) chemotherapy after progression is unclear. We assessed clinical outcomes of 2L chemotherapy for disease that progressed on 1L nab-P+GEM. Materials and Methods Among the 203 patients previously treated with 1L nab-P+GEM for mPDAC at Asan Medical Center, between February and December 2016, records of 120 patients receiving 2L chemotherapy after progression on nab-P+GEM were retrospectively reviewed. The response rate and survival were evaluated along with analysis of prognostic factors. Results Fluoropyrimidine-oxaliplatin doublets (FOLFOX or XELOX) were used in 78 patients (65.0%), fluoropyrimidine monotherapy in 37 (30.8%), and liposomal irinotecan plus fluorouracil in two (1.7%). The median progression-free survival (PFS) and overall survival (OS) were 3.29 months and 7.33 months from the start of 2L therapy. Fluoropyrimidine-oxaliplatin regimens and fluoropyrimidine monotherapy did not yield significantly different median PFS (2.89 months vs. 3.81 months, p=0.40) or OS (7.04 months vs. 7.43 months, p=0.86). A high neutrophil-lymphocyte ratio (> 2.2) and a short time to progression with 1L nab-P+GEM (< 6.4 months) were independent prognostic factors of poor OS with 2L therapy. Conclusion 2L fluoropyrimidine-oxaliplatin doublets and fluoropyrimidine monotherapy after failure of 1L nab-P+GEM had modest efficacy, with no differences in treatment outcomes between them. Further investigation is warranted for the optimal 2L chemo-regimens and sequencing of systemic chemotherapy for patients with mPDAC.
참고문헌 (23)
- Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial", J Clin Oncol, 15, pp.2403~2413 (1997)
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
- Kang J, "Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer : retrospective analysis", Invest New Drugs, 36, pp.732~741 (2018)
- Abrams TA, "Patterns of chemotherapy use in a U.S.-based cohort of patients with metastatic pancreatic cancer", Oncologist, 22, pp.925~933 (2017)
- "NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Pancreatic adenocarcinoma. Version 1.2019" (2019)[URL]
- Ducreux M, "Cancer of the pancreas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 26(Suppl 5), pp.v56~v68 (2015)
- ESMO Guidelines Committee, "Appendix 6: cancer of the pancreas:MCBS eUpdate published online 20 June 2017 (www. esmo.org", Guidelines, Ann Oncol, pp.2017, 28(suppl_4)[DOI]
- Oettle H, "Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer : outcomes from the CONKO-003 trial", J Clin Oncol, 32, pp.2423~2429 (2014)
- Gill S, "PANCREOX : a randomized phase III study of fluorouracil", leucovorin with or without oxaliplatin for secondline advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy, 2016, pp.34, 3914~3920
- Wang-Gillam A, "Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy(NAPOLI-1) : a global, randomised, open-label, phase 3 trial", Lancet, 387, pp.545~557 (2016)
- Hwang I, "Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine : implication of inflammation-based scores", Invest New Drugs, 37, pp.584~590 (2019)
- Morizane C, "A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer", Cancer Chemother Pharmacol, 63, pp.313~319 (2009)
- Chiorean EG, "Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer", Br J Cancer, 115, pp.188~194 (2016)
- Ueno H, "Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study", J Clin Oncol, 31, pp.1640~1648 (2013)
- Ohkawa S, "Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer", Br J Cancer, 112, pp.1428~1434 (2015)
- Yoo C, "A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabinerefractory advanced pancreatic cancer", Br J Cancer, 101, pp.1658~1663 (2009)
- Glassman DC, "Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience", BMC Cancer, 18, pp.693~ (2018)
- Yoo C, "Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU", leucovorin (5-FU, J Clin Oncol, pp.2019, 37(4 Suppl)[DOI]
- Pusceddu S, "Comparative effectiveness of gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer : a systematic review and metaanalysis", Cancers(Basel), 11, pp.E484~ (2019)
- Sugiura T, "Prognostic scoring system for patients who present with a gastric outlet obstruction caused by advanced pancreatic adenocarcinoma", World J Surg, 41, pp.2619~2624 (2017)
- Chen Y, "Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis : a retrospective analysis in advanced pancreatic ductal adenocarcinoma", Sci Rep, 7, pp.753~ (2017)
- Yang JJ, "Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer : a meta-analysis", World J Gastroenterol, 21, pp.2807~2815 (2015)